Emerging Biomarkers in Head and Neck Cancer Development and Progression
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 5032
Special Issue Editor
2. UNIPRO—Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), Gandra, Portugal
Interests: oral cancer; oral leukoplakia; prognostic markers; laser; immunohistochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Head and neck cancer is a major public health problem, as it is the sixth most common cancer worldwide and has consistently had low survival rates even in recent decades.
Head and neck tumorigenesis involves an accumulation of multiple genetic and epigenetic alterations from several important pathways providing capabilities to cancer development and progression such as sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis and activating invasion and metastasis, reprograming cellular energetics, and evading immune destruction.
The identification of these altered molecular pathways may originate biomarkers able to differentiate tumors with a more or less aggressive behavior. These biomarkers may have a translational clinical potential to identify and diagnose specific tumors and stratify patients with greater precision to the most appropriate treatment plan. Moreover, these molecules may become molecular therapeutic targets or even predictive markers of treatment response.
New genomic, epigenomic or transcriptomic methods of evaluating single and multiple-cell alterations have provided new horizons on biomarker discovery, evaluation, and validation of the several aspects of the biopathology of these cancers and related diseases.
In the view of this, we invite authors to submit their research or review articles describing the most recent evaluations on biomarkers with potential use in diagnosis, treatment response prediction, and prognosis of head and neck cancers, including also potential malignant disorders to be published in this Special Issue.
Dr. Luís Monteiro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- predictive biomarker
- DNA instability
- cell cycle
- apoptosis
- immuno-oncology
- genomic and epigenomic analysis
- immunohistochemistry
- In situ hybridization
- diagnosis
- prognosis
